GlassScriptPhysician profile
Lori R Johnson
NPI 1386648129
$4,893.76
in general payments reported to CMS, 2019-2025
21 companies · $1,515 in 2025
The $1,515 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.31 · 2020: $29.16 · 2021: $211 · 2022: $748 · 2023: $1,334 · 2024: $1,011 · 2025: $1,515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,719 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,719.04 |
| Education | $142.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,259.11 | 2022-2025 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $962.13 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $700.32 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $553.44 | 2021-2025 | |
| Genentech USA, INC. | $460.18 | 2021-2025 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $185.31 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $185.08 | 2022-2024 | Cuvitru, Gattex |
| Novartis Pharmaceuticals Corporation | $153.74 | 2019-2025 | |
| Kaleo, INC. | $89.03 | 2022-2023 | Auvi-Q |
| Pfizer INC. | $72.52 | 2021-2023 | |
| Galderma Laboratories, L.P. | $60.93 | 2025 | Nemluvio |
| Csl Behring | $40.94 | 2022-2023 | Hizentra |
| Aimmune Therapeutics, INC. | $37.74 | 2022 | |
| Welch Allyn | $24.97 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.26 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $18.10 | 2022 | |
| Greer Laboratories, INC. | $17.75 | 2023 | Oralair |
| Pharming Healthcare, INC. | $15.11 | 2025 | Ruconest |
| Blueprint Medicines Corporation | $14.87 | 2023 | Ayvakit |
| Incyte Corporation | $12.51 | 2022 | |
| Itamar Medical INC | $11.72 | 2023 | Watchpatone |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.